Detrimental influences of intraluminally-administered sclerotic agents on surrounding tissues and peripheral nerves: An experimental study

Abstract The minimally-invasive nature of sclerotherapy makes it one of the first treatment options for venous malformations, although treatment-related complications, such as peripheral nerve paralysis, have been reported in some clinical cases. However, no studies of the aetiology of the detrimental effects of intraluminally-administered sclerotic agents on the surrounding tissues, including the peripheral nerves, have yet been published. This study therefore investigated the influences of intraluminally-administered sclerotic agents on the tissues surrounding the injection site using a newly-developed rat femoral vein model. Using this model, the effects of absolute ethanol, 5% ethanolamine oleate, and 1% polidocanol were compared histologically with those of normal saline controls. Fluorescein isothiocyanate-conjugated agents were administered and the leakage of sclerotic agents through the venous wall was evaluated by fluorescence microscopy. Damage to the adjacent femoral nerve was quantitatively evaluated by counting the numbers of axons in cross-sections. All the sclerotic agents caused vascular wall injuries and leakage into the surrounding tissues. The number of axons in the femoral nerve was significantly reduced following administration of absolute ethanol or 5% ethanolamine oleate, compared with normal saline. The results of this study suggest that sclerotic agents commonly leak out the vascular lumen, and some agents can cause adjacent nerve injury. It is important to be aware of this type of complication of sclerotherapy for venous malformations when selecting appropriate therapeutic interventions.

[1]  K. Harii,et al.  Subcutaneous Injection of Normal Saline Prevents Cutaneous Complications of Ethanol Sclerotherapy for Superficial Vascular Lesions: An Experimental Study , 2011, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[2]  K. Harii,et al.  Efficacy and evaluation of safety of sclerosants for intramuscular venous malformations: Clinical and experimental studies , 2010, Scandinavian journal of plastic and reconstructive surgery and hand surgery.

[3]  K. Harii,et al.  Experience of sclerotherapy and embolosclerotherapy using ethanolamine oleate for vascular malformations of the head and neck , 2009, Scandinavian journal of plastic and reconstructive surgery and hand surgery.

[4]  T. Wakefield,et al.  Mechanisms of venous thrombosis and resolution. , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[5]  Yuhei Yamamoto,et al.  Evaluation of the Sclerotherapeutic Efficacy of Ethanol, Polidocanol, and OK‐432 Using an In Vitro Model , 2007, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[6]  Yuh-Cherng Guo,et al.  Facial nerve conduction after sclerotherapy in children with facial lymphatic malformations: report of two cases. , 2007, The Tohoku journal of experimental medicine.

[7]  A. Hirano,et al.  Therapeutic Choice for Craniofacial Venous Malformations , 2006, The Journal of craniofacial surgery.

[8]  D. Freedman,et al.  An injectable tissue-engineered embolus prevents luminal recanalization after vascular sclerotherapy. , 2005, Journal of pediatric surgery.

[9]  F. Allaert,et al.  Immediate and Midterm Complications of Sclerotherapy: Report of a Prospective Multicenter Registry of 12,173 Sclerotherapy Sessions , 2005, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[10]  C. Mounayer,et al.  Percutaneous sclerotherapy for venous malformation of the lips: a retrospective study of 23 patients , 2000, Neuroradiology.

[11]  J. Mulliken,et al.  Sclerotherapy of craniofacial venous malformations: complications and results. , 1999, Plastic and reconstructive surgery.

[12]  L. Cantley,et al.  Vascular Dysmorphogenesis Caused by an Activating Mutation in the Receptor Tyrosine Kinase TIE2 , 1996, Cell.

[13]  L. Greenfield,et al.  Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[14]  A. D. Lorimier,et al.  Sclerotherapy for venous malformations. , 1995, Journal of pediatric surgery.

[15]  G. Sebag,et al.  Soft-tissue venous malformations in children: percutaneous sclerotherapy with Ethibloc. , 1991, Radiology.

[16]  K. Orikasa [Studies on the damage of the cultured endothelial cells and K-562 cells by sclerosants (ethanolamine oleate, Aethoxysklerol and absolute ethanol) used in the treatment of esophageal varices]. , 1989, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[17]  J. Michael Textbook of Medical Physiology , 2005 .